Oncology Drug Development: Rethinking FDA Oversight
Day Two
About This Event

While controversy has raged over the Food and Drug Administration’s (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA’s role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied researchers. The celebrated new tools of molecular biology, matched with new thinking about clinical trials and statistical analysis, have opened the door to faster development, testing, and approval of cancer drugs. But moving innovative new cancer drugs from laboratory to bedside has taken longer than almost anyone expected, especially for such dramatic innovations as the harnessing of the immune system to fight cancer.

At this conference, experts from academia, the National Institutes of Health, and the pharmaceutical research industry will be joined by current and former FDA officials, including former commissioners David Kessler and Mark B. McClellan. Participants will address some of the thorniest issues in cancer drug development, including clinical trial design, statistical analysis of trial results, and the feedback from FDA decisions to the drug development process.

This event is cosponsored by AEI and the University of Chicago Law School.

March 13
8:15 a.m.
Registration and Breakfast
8:30 a.m.
John E. Calfee, AEI
Scott Gottlieb, M.D., AEI
8:45 a.m.
Panel I: FDA Regulation and the R&D Environment
Richard A. Epstein, University of Chicago Law School
Richard Miller, M.D., Pharmacyclics
Tomas Philipson, AEI and University of Chicago
10:15 a.m.
Panel II: Clinical Trial Design
David Alberts, M.D., Arizona Cancer Center
James Doroshow, M.D., National Cancer Institute
Gwen Fyfe, M.D., Genentech
Bruce Cheson, M.D., Georgetown University Hospital
12:15 p.m.
Keynote Speaker:
Andrew C. von Eschenbach, M.D., Food and Drug Administration
1:30 p.m.
Panel III: Statistical Issues in Analyzing Clinical Trial Data
Anup Malani, University of Chicago Law School
Richard Simon, National Institutes of Health
Mark van der Laan, University of California, Berkeley
John E. Calfee, AEI
3:30 p.m.
Panel IV: Puzzles in FDA Standards for Oncology Drug Approval
John E. Calfee, AEI
Ken Carson, M.D., Feinberg School of Medicine, Northwestern University
Robert Ward, George Washington University School of Medicine
Richard Miller, M.D., Pharmacyclics
5:00 p.m.
Adjournment and Reception
March 14
9:00 a.m.
Panel V: FDA Past, Present, and Future
Nancy L. Buc, Buc and Beardsley
Scott Gottlieb, M.D., AEI
David Kessler, M.D., University of California, San Francisco, School of Medicine
Mark B. McClellan, M.D., AEI and Brookings Institution
Douglas Throckmorton, M.D., Food and Drug Administration
Richard A. Epstein, University of Chicago Law School
11:15 a.m.
Roundtable Discussion among Speakers
John E. Calfee, AEI
12:30 p.m.
Also Visit
AEIdeas Blog The American Magazine

What's new on AEI

AEI Election Watch 2014: What will happen and why it matters
image A nation divided by marriage
image Teaching reform
image Socialist party pushing $20 minimum wage defends $13-an-hour job listing
AEI Participants




Tomas J.
AEI on Facebook